Clinical trial · Observational
A Study of Patients With HER2-Positive Metastatic Breast Cancer
registHER: An Observational Cohort Study of Patients With HER2 Positive Metastatic Breast Cancer
NCT00105456CI-TRIAL-00003422completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a prospective observational cohort study designed to describe effectiveness and safety (treatment outcomes and clinically significant cardiac adverse events, respectively) in patients with HER2-positive metastatic breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Signed Informed Consent document (unless the IRB has granted a waiver of consent) * Signed Authorization for the Use and Disclosure of Health Information document * HER2-positive breast cancer * Initial diagnosis of metastatic (Stage IV) breast cancer within 6 months prior to enrollment * Availability of cancer-specific historical data points in the patient's medical records Exclusion Criteria: * There are no exclusion criteria for participation in this trial
References
Publications (1)
- DERIVEDYardley DA, Tripathy D, Brufsky AM, Rugo HS, Kaufman PA, Mayer M, Magidson J, Yoo B, Quah C, Ulcickas Yood M. Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER. Br J Cancer. 2014 May 27;110(11):2756-64. doi: 10.1038/bjc.2014.174. Epub 2014 Apr 17. PMID 24743708